Southern Research’s Post

READ: The San Francisco Business Times recently published a profile on Carol Mimura, who serves as Assistant Vice Chancellor for Intellectual Property & Industry Research Alliances (IPIRA) at the University of California, Berkeley and was one of the inaugural recipients of The Bayh-Dole Coalition American Innovator Award! Dr. Mimura spoke about her long and impactful career in technology transfer, explained how she and Berkeley are currently working to foster innovation, and offered advice for academic entrepreneurs. "2,000 [patents] are still alive and nearly 300 companies have spun out with IP licenses from Berkeley, creating about 800 products to date. That’s about $280 million in IP license revenue so far. We’re doubling down to get more value from equity, and in June, our chancellor gave us the opportunity to manage equity at the campus level. We’ve received about $49 million from the sale of equity so far, including startups in biotech, software and physical sciences and engineering fields." "We do this work to see something — sometimes it’s just a glimmer of hope — that will someday be translated into products and services that benefit us all…[T]ech transfer is a team sport that requires the coordinated efforts of dozens of people." "Follow your instincts. Be open to any opportunities. Take advantage of the vast innovation ecosystem that is here to help you. Be inclusive. Make sure you don’t populate your workplace only with people who agree with you, because you need all kinds of input at different times and from all backgrounds. And truly and intently listen." Read the full article: https://lnkd.in/eMxacAgV #BayhDole #BayhDoleFOAI #innovation #innovator #techtransfer #university #research #patents #IP #inventions #science #entrepreneurship

Are you looking to expand your life science operations into the #UnitedStates? Frederick County, Maryland offers a strategic location for your next office. Here’s why: 1. Proximity to Innovation: Frederick County is home to the National Cancer Institute (NCI) at Fort Detrick, a global leader in oncology, infectious diseases, and biodefense research. This proximity fosters collaboration opportunities with leading researchers and access to state-of-the-art facilities. 2. Skilled Workforce: With a rich talent pool from local universities like Hood College and Mount St. Mary's University and proximity to the Baltimore-Washington metro area, Frederick County offers access to a highly educated and specialized workforce crucial for advancing your life science work. 3. Business-Friendly Environment: The county provides a supportive ecosystem for businesses, including a soft landing program and incentives tailored to foster innovation in biotechnology and pharmaceutical sectors. 4. Infrastructure and Connectivity: Situated near major transportation routes like Interstates 70 and 270, Frederick County ensures seamless connectivity to major East Coast markets and 3 international airports, facilitating efficient logistics and distribution. If you’re considering a strategic move into the #USA life sciences market, #FrederickCountyMD should undoubtedly be on your list. Our strategic advantages and supportive ecosystem can propel your business to new heights in life sciences like the companies in the article below! Let’s explore how Frederick County can be the perfect launchpad for your next phase of growth! Feel free to stop by #SelectUSA #Maryland #Booth202 for more information or to discuss potential opportunities. #LifeSciences #Biotechnology #Pharmaceuticals #Innovation #FrederickCounty #BusinessExpansion #Global

We are excited to announce the closing of Cybin’s acquisition of Small Pharma, creating a leading clinical-stage company dedicated to transforming the standard of care for mental health conditions. Together, the combined company has: • The largest, most advanced, well-protected deuterated DMT clinical program • The largest psychedelic IP portfolio, with over 30 patents granted and 160 patents pending • Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy • Four clinical trials expected in 2024 supporting the advancement of the combined pipeline “The closing of this transaction marks a significant milestone in Cybin’s growth trajectory, firmly establishing us as a leader in the psychedelics sector,” said Doug Drysdale, Chief Executive Officer of Cybin. “We welcome the Small Pharma scientists and leaders who are joining the Cybin team, as we look to leverage the many synergies and drive value for shareholders.” Learn more: https://lnkd.in/gfZJeDzk #ChangingMinds #researchanddevelopment #cybin #psychedelicresearch #clinicalresearch #mentalhealthresearch #CybinInc #DrugDevelopment #Biotech #MentalHealth               

Endowments are especially important in #pediatric #device development since industry often does not see the financial return on pediatric devices, but pediatric-specific devices are desperately needed. Feel free to reach out to me at #GeorgiaTech’s #PediatricInnovationNetwork to discuss the possibilities.

Dec 2018 – Dec 2023. 5 years ago, my journey in Gain Therapeutics officially started. I am proud to be associated with Gain, as we moved together as a team from a handful of highly knowledgeable scientists and admins to a NASDAQ listed company and now to a clinical stage one. I would like here to thank (the list would be very long) all the current and past colleagues for their dedication and passion, the current and past external academic collaborators for their science, the patient and research organizations for their wisdom and collaboration. The US+EU+Swiss+Ticino ecosystem and grant organizations for their support, the initial and current investors for believing in us and last but not least Gain’s current and past board members who strategically have and are supporting Gain. Finally, I would like to express my gratitude to the first CEO (Lorenzo Leoni) and Gain’s chairman (Khalid Islam) for having offered me the position. I also would like to thanks Eric Richman for having transitioned us as CEO to the NASDAQ and Matthias Alder for having coordinated as CEO the transition to the clinic. And thanks to Alessandro Bossi for the initial contact to this project (now a solid reality). #ganx #gaintherapeutics #usa #eu #switzerland #ticino #ecosystem #nasdaq #parkinsonsdisease #rarediseases #drugdevelopment #researchcollaboration #science #finance #clinicalresearch #stars #allostery

The wait is over! Fierce Biotech Fierce 15 is here! Nominations starting today in search of the best and brightest in biotech.  Send in your suggestions for the fiercest companies in the game now! 👉 https://lnkd.in/eMqebHWa 📢 Follow Fierce Life Sciences Events for the latest news and updates #FierceBiotech #FiercePharma #Fierce15

✨ Exciting News from Harbour BioMed! Just now, Harbour BioMed released the annual financial results for the full year 2023. In the press release, Harbour BioMed reported a net profit for the first time, with a profit of US$22.8 million for the year ended 31 December 2023. Other financial highlights include:   ✨ Revenue: The revenue for the full year 2023 is US$89.5 million, which increased significantly by US$48.8 million, or 119.9%, compared with US$40.7 million for the year ended 31 December 2022. ✨ Research and development costs: The research and development expenses decreased by 66.6%, from US$135.1 million in 2022 to US$45.1 million in 2023. ✨ Administrative expenses: The administrative expenses decreased by 28.6%, from US$27.3 million in 2022 to US$19.5 million in 2023. Explore more details here: https://lnkd.in/gfGinG6F #HarbourBioMed #2023 #FinancialResults #Growth

The launch is nearing! Keep tabs on the upcoming funding call in ODIN - our patent-free collaboration platform for drug discovery and better diagnostics. We have lined up a few events where you can get the information you need and perhaps meet future project partners? 1.     The ODIN kick-off conference On 27 May, we’ve planned a day full of information and networking in Copenhagen. We believe that the conference is the perfect starting point for new collaborations across industry and academia. Participation is of course free of charge and anyone interested can join us by signing up here: https://lnkd.in/d5pYfdeS   2.     ODIN information meetings In case you’re not able to make it to the kick-off conference, we’ve planned a series of information meetings at the Danish partner universities. At these 1-hour events, I’ll give an in-depth introduction to ODIN and let you in on the details of how to apply for project funding for open research collaborations. You can find the time and place, which suits you best on ODIN’s website: https://lnkd.in/dbZaRzVV   3. Also, please follow ODIN’s LinkedIn page to learn more about what an ODIN project looks like. In the following weeks, ODIN’s LinkedIn page will give you examples of previous ODIN projects to let you in on the many different ways of approaching open collaborations and what the grant holders learned. Find ODIN’s LinkedIn page here: https://lnkd.in/dsXQFS-S   If you have questions regarding ODIN, you are always welcome to reach out.

The Swiss HLG 2024 conference starts in beautiful Montreux on Sunday evening. We are thrilled to have Ed Saltzman, Senior Strategic Advisor at Lumanity as Key Note speaker. I caught up with Ed on his Key Note last night and his analysis and insights blew my mind - conference attendees are in for a real treat. Ed's topic is: Biopharma dealmaking: Time for a Rethink?   Biotechs have to accomplish two overarching goals to achieve a lucrative licensing deal with large pharma: 1) move their products through multiple stages of clinical and regulatory de-risking and; 2) demonstrate that these products have substantial revenue potential (now $1bn or more). Most pre-commerical biotechs continue to prioritize the first goal, but in today’s dynamic and volatile commercial environment, especially in the US, most fail to secure deals because they cannot make a compelling case that their asset can deliver on the second one. In 2009 when capital to fund development though PoC de-risking was scarce, Ed proposed a new value-driving concept for sellers: Proof of Relevance (PoR). PoR is a less capital intensive and faster route to de-risking assets prior to traditional PoC, by making a compelling case for an asset’s therapeutic and thus commercial value. By focusing only on clinical and regulatory de-risking, sellers were missing this opportunity.   Despite recent very challenging capital markets, a record number of companies have raised sufficient capital to move past PoC. Unfortunately, this has led to the value of establishing PoR being overlooked. The result is a surplus of clinically de-risked assets weighed down by unattractive commercial risk profiles.   Pharma perceives only a minority of assets to have the inherent, compelling commercial prospects needed to pass minimum revenue thresholds. These “corner property” assets are the basis of today’s mega-deals. However, the reality is that the vast majority of biotechs with post-POC assets are unlikely to achieve any large pharma deal unless PoR is as compelling as PoC.   In his Key Note talk, Ed will share his thoughts on how biotechs can best address this critical challenge, followed by discussion and Q&A led by Nigel Sheail of Versant Ventures. It's not too late to register and hear Ed's insights, please register here ➡ https://lnkd.in/daxgmUHa You can now find Ed's presentation here: https://lnkd.in/gH5wAUQ6 #swisshlg #biopharma #dealmaking #innovation #networking

✨𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭✨- Cleveland Diagnostics, Inc. - "Improving cancer decisions"... 🧐 𝑫𝒊𝒅 𝒚𝒐𝒖 𝒌𝒏𝒐𝒘 Cleveland Diagnostics, Inc. provides innovative blood tests designed to detect the presence or absence of diseases. Their initial offering, IsoPSA, addresses the longstanding demand for a more straightforward and distinct method to eliminate the need for unnecessary prostate biopsies. #IsoPSA has the potential to decrease the number of unnecessary prostate biopsies by as much as 55%. In the United States, up to 75% of the outcomes from prostate biopsies reveal a lack of high-grade disease. By specifically targeting PSA proteins originating from #cancer cells, the IsoPSA test aids in identifying men for whom a biopsy would not be beneficial. 🎉 𝐓𝐡𝐞𝐲 kickstarted the new year by raising a huge $75 million in venture funding, led by Novo Holdings!! 🌐 𝐖𝐚𝐧𝐭 𝐭𝐨 𝐥𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞, here is a link to their web page – https://lnkd.in/df7saWpH 🥼 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐭𝐢𝐦𝐞𝐬 ahead for Arnon Chait and the rest of the Cleveland Diagnostics, Inc. team! 👏🧬⚡🔬🎉🧪 #ivd #diagnostics #lifescience 🔗Source: